DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for hepatorenal syndrome — screening already-approved drugs against its 13-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHepatorenal syndrome maps to a 13-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hepatorenal syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor beta 3 (ADRB3) — ADRB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet aledrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9IJE · 2.34 Å · ligand L-EPINEPHRINE (ALE). Experimental structure, not a prediction.
What the evidence adds up to
A 2004 case report described reversal of hepatorenal syndrome using oral midodrine, subcutaneous octreotide, and intravenous albumin, but this is a single case and not a trial. A 2022 review states that pharmacological treatments have shown a mortality benefit, but that the ideal treatment remains liver transplantation with or without simultaneous kidney transplantation, and that further research is needed to optimise both pharmacologic and nonpharmacologic approaches.
A 2025 Brazilian study of 44 patients with 49 episodes of suspected hepatorenal syndrome in intensive care found that 77% died, 32% from multiple organ failure, 29% from septic shock, and 27% from hypovolaemic shock. The median total treatment cost per patient was Int$14,819, and the median intensive care stay was 11 days. The diagnosis was presumed in 43% of episodes because not all diagnostic criteria were met. Alcoholic cirrhosis was the main cause (43%), and 59% of patients were Child-Pugh Class C at admission with a mean MELD score of 24.6.
The 2025 study notes that timely diagnosis and management may reduce mortality, resource use, and costs, but does not report any survival benefit from any specific drug regimen. The 2004 case and the 2022 review both point to the need for better evidence, but no randomised controlled trial data for midodrine, octreotide, or any other drug combination are provided in these abstracts. What is missing is a properly powered, randomised trial with clear diagnostic criteria, adequate patient stratification by cirrhosis severity, and funding to test whether any drug combination improves survival beyond the current high mortality rate.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Postgraduate Medicine · 2004 · 3 citations
Reconsidering hepatorenal syndrome
AbstractFor many years, hepatorenal syndrome was considered a uniformly and rapidly fatal complication of end-stage liver disease. Although the syndrome still carries a poor long-term prognosis, increased understanding of its hemodynamic derangements has led to new pharmacologic treatments that significantly improve short-term outcomes. In this article, Drs Tong, Hurley, and Hayashi discuss a case of remarkable reversal of hepatorenal syndrome with use of oral midodrine hydrochloride, subcutaneous octreotide acetate, and intravenous albumin. The authors highlight the great progress that has been made in this field and review new therapeutic options that are on the market or under study. It is important for physicians who are caring for patients with hepatorenal syndrome to know about and consider the available treatments before an approach of "supportive care only" is taken.
Einstein (São Paulo) · 2025 · 0 citations · open access
Hepatorenal Syndrome: direct treatment costs and characteristics of patients admitted to intensive care
AbstractBACKGROUND: Hepatorenal Syndrome is a potentially reversible syndrome of endstage cirrhosis. It is a severe complication of cirrhosis that involves a high mortality rate and a significant economic impact on the healthcare system. This study shows the costs of the resources used for disease management and complications to be Int$14,189. Quantifying this figure contributes to an understanding of the economic impact of Hepatorenal Syndrome on patient survival. OBJECTIVE: The purpose of this study was to describe the direct medical costs incurred in Brazil for the treatment of Hepatorenal Syndrome in intensive care and intermediate therapy care units, and to investigate the impact of this syndrome on patient survival. METHODS: This longitudinal observational retrospective study included patients with Hepatorenal Syndrome admitted to the intensive and intermediate therapy care units of a public tertiary hospital. The cost generated by each patient was the sum of the direct costs and overheads. RESULTS: Forty-four patients with 49 episodes of suspected Hepatorenal Syndrome were analyzed, 73% male, with a mean age of 55 years (SD= 11). Diagnosis was presumed in 21 episodes (43%), because not all of the Ascites International Club's criteria were met. Alcoholic cirrhosis was the main etiology (43%); 59% of the patients were Child-Pugh Class C at admission, with a mean (SD) model for end-stage liver disease score of 24.6 (8). Seventy-seven percent of the patients died, 32% from multiple organ failure, 29% of septic shock and 27% of hypovolemic shock. The median (IQR) of the total treatment cost for each patient was Int$14,819 (8,732-23,854). The median (IQR) length of intensive care unit stay in intensive care was 11 days (7-19). Patients with a presumed diagnosis did not have a higher hospitalization cost (p=0.249) than those with true Hepatorenal Syndrome. CONCLUSION: The treatment of Hepatorenal Syndrome represents a significant cost, and new resource allocation in strategic areas, such as the treatment and monitoring of patients with cirrhosis, is necessary to improve their outcomes. BACKGROUND: ■ The treatment of Hepatorenal Syndrome places a huge economic burden on healthcare systems. BACKGROUND: ■ Cost analysis studies of Hepatorenal Syndrome management can help to rationally allocate resources in healthcare. BACKGROUND: ■ Timely diagnosis and management of Hepatorenal Syndrome may reduce mortality, resource utilization and costs.
South Russian Journal of Therapeutic Practice · 2022 · 0 citations · open access
Hepatorenal syndrome: new insights about treatment (part III)
AbstractHepatorenal syndrome is a common and serious complication in cirrhotic patients, leading to significant morbidity and mortality. Although pharmacological treatments have shown mortality benefit, the ideal hepatorenal syndrome treatment option is liver transplantation with or without simultaneous kidney transplantation. Further research is required to optimize pharmacologic and nonpharmacologic approaches to treatment. An analysis of literature reviews, clinical studies, experimental research, clinical recommendations from PubMed / Medline and ELIBRARY databases was carried out for 7 keywords according to the review topic.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
